Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Gw Pharma ADR (NQ: GWPH )

214.85 USD UNCHANGED
Streaming Delayed Price Updated: 2:50 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Gw Pharma ADR

< Previous 1 2
...
19 20 21 22 23 24 25 26 Next >
Pharma Stocks under Review -- Impax Laboratories, Sanofi, GW Pharma, AcelRx Pharma, and Salix Pharma
Editor Note: For more information about this release, please scroll to bottom 
From PR Newswire
NTRR: New York Joins Rapidly Growing U.S. Cannabis Market
From Business Wire News Releases
Patent Case Settlements, FDA Rulings, Upcoming Investor Day, Product Launching, and Closing of Offering - Analyst Notes on Teva, AstraZeneca, Salix, Mylan and GW
Editor Note: For more information about this release, please scroll to bottom. 
From PR Newswire
NTRR Eyes July Release for New Cutting-Edge Vapor Pen
From Business Wire News Releases
GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Totaling Approximately $169.8 Million on the NASDAQ Global Market and Full Exercise of Underwr
From GlobeNewswire News Releases
Conference Call Schedules, Acquisitions, and Public Offerings - Analyst Notes on Johnson & Johnson, Merck, GW, Endocyte and AVEO
Editor Note: For more information about this release, please scroll to bottom 
From PR Newswire
GW Pharmaceuticals plc Announces Pricing of U.S. Public Offering of ADSs Totalling Approximately $148 Million on NASDAQ Global Market
From GlobeNewswire News Releases
GW Pharmaceuticals Announces Proposed Public Offering of ADSs
From GlobeNewswire News Releases
GW Pharmaceuticals Announces Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy From Physician-Led Expanded Access Treatment Program
From GlobeNewswire News Releases
Equity Coverage on Pharma Industry -- Research on AbbVie, AcelRx Pharma, Bristol-Myers Squibb, and GW Pharma
Editor Note: For more information about this release, please scroll to bottom. 
From PR Newswire
FDA Drug Approvals, Dividends, Fast Track Designation, Event Sponsorship, and Expansion of Role - Analyst Notes on Biogen Idec, UnitedHealth Group, GW Pharmaceuticals, Questcor and Cigna
Editor Note: For more information about this release, please scroll to bottom 
From PR Newswire
GW Pharmaceuticals Announces Epidiolex(R) Receives Fast Track Designation From FDA for the Treatment of Dravet Syndrome
From GlobeNewswire News Releases
Development of Cannabinoid-Based Therapies Becoming More Prevalent by Leaps and Bounds - CBIS Forges Ahead with Cannabis-Based Cancer Treatments
From PR Newswire
Cannabinoid-Based Therapies , CBIS Forges Ahead with Cannabis-Based Cancer Treatments
Tags banking/finance/investment business/economy healthcare/pharmaceuticals
From EIN Presswire
Clinical Studies for Cannabis Based Drug Development Targets Multitude of Medical Treatments - CBIS Issues CBN Patent and R&D Guidance
From PR Newswire
NTRR Preps Vapor Pen for Summer Release Into Booming Marketplace
From Business Wire News Releases
Cannabis Briefing for Marijuana Sector - Company Enters Agreement to Acquire Assets of California Medical Cannabis Dispensary
From PR Newswire
Pharmaceutical Development & Medical Cannabis Expand at an Aggressive Rate - Company Attracts Major Attention at WebCongress Conference in San Francisco
From PR Newswire
Cannabis Based Medicines Gain Traction as Research & Development Ramp up - Company Looks to Develop Topical Cannabis Medicine to Treat Skin Cancer
From PR Newswire
Health Care Sector Equities Technical Analysis -- Research on CombiMatrix, Quintiles Transnational Holdings, Pfizer, and GW Pharma
Editor Note: For more information about this release, please scroll to bottom. 
From PR Newswire
Research & Development Kick Into High Gear For Cannabis Based Medicine - New Collaboration Agreement For Development of Cannabis Based Skin Cancer Medicine
From PR Newswire
GW Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
From GlobeNewswire News Releases
GW Pharmaceuticals plc Reports Second Quarter 2014 Financial Results and Operational Progress
Conference Call Today at 8:00 a.m. ET, 1:00 p.m. BST 
From GlobeNewswire News Releases
GW Pharmaceuticals Receives Investigational New Drug (IND) From FDA for Phase 2/3 Clinical Trial of Epidiolex(R) in the Treatment of Dravet Syndrome
From GlobeNewswire News Releases
GW Pharmaceuticals Appoints Dr. Kenneth Sommerville as VP, Clinical Science
Position Created to Support U.S. Medical Affairs and Regulatory Activities Related to Epilepsy Programs 
From GlobeNewswire News Releases
Earnings Results, Acquisitions, Drug Designations, Dividend Authorizations, and Licensing Agreements - Analyst Notes on AstraZeneca, Furiex, GW, Techne and Agenus
Editor Note: For more information about this release, please scroll to bottom. 
From PR Newswire
GW Pharmaceuticals to Report Q2 2014 and Half Year Financial Results and Host Conference Call on 7 May, 2014
From GlobeNewswire News Releases
NTRR Prepares to Bring New Products Online
From Business Wire News Releases
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain
From GlobeNewswire News Releases
Drug Approvals, Quarterly Earnings Releases, and Stock Price Updates - Analyst Notes on Merck, Johnson & Johnson, UnitedHealth, Celgene and GW
Editor Note: For more information about this release, please scroll to bottom. 
From PR Newswire
< Previous 1 2
...
19 20 21 22 23 24 25 26 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.